Hims & Hers Health (HIMS) Non-Current Deferred Tax Liability (2025 - 2026)
Hims & Hers Health (HIMS) posted Non-Current Deferred Tax Liability of $23.5 million for Q1 2026, down 18.52% sequentially from $28.9 million in Q4 2025.
Hims & Hers Health (HIMS) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Hims & Hers Health has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $23.5 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $23.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.5 million (changed N/A YoY) and the FY2025 annual result came in at $28.9 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability retreated to $23.5 million in Q1 2026 per HIMS's latest filing, from $28.9 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $31.2 million in Q3 2025 and troughed at $23.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Hims & Hers Health | 7.42 Bn | 6.57 Bn | 480.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.93 Mn |
| Jun 30, 2026 | 30.93 Mn |
| Mar 31, 2026 | 23.51 Mn |
| Mar 31, 2026 | 23.51 Mn |
| Dec 31, 2025 | 28.86 Mn |
| Dec 31, 2025 | 28.86 Mn |
| Sep 30, 2025 | 31.21 Mn |
| Sep 30, 2025 | 31.21 Mn |